1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Maryland >
  6. AstraZeneca Acquires MedImmune

M&A Deal Summary

AstraZeneca Acquires MedImmune

On June 1, 2007, AstraZeneca acquired medical products company MedImmune for 15.6B USD

Acquisition Highlights
  • This is AstraZeneca’s 1st transaction in the Medical Products sector.
  • This is AstraZeneca’s 2nd largest (disclosed) transaction.
  • This is AstraZeneca’s 1st transaction in the United States.
  • This is AstraZeneca’s 1st transaction in Maryland.

M&A Deal Summary
Date 2007-06-01
Target MedImmune
Sector Medical Products
Buyer(s) AstraZeneca
Deal Type Add-on Acquisition
Deal Value 15.6B USD

Target

MedImmune

Gaithersburg, Maryland, United States
MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With approximately 2,000 employees worldwide, MedImmune is headquartered in Maryland.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

AstraZeneca

Cambridge, United Kingdom
Category Company
Founded 1992
Sector Life Science
Employees83,100
Revenue 54.1B USD (2024)
DESCRIPTION
Main office on AstraZeneca's campus in Waltham, Massachusetts.
Main office on AstraZeneca's campus in Waltham, Massachusetts.

AstraZeneca is a global biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in several major disease areas, including oncology, cardiovascular, renal & metabolism, and respiratory & immunology. AstraZeneca was founded in 1992 and is based in Cambridge, United Kingdom.

DEAL STATS #
Overall 3 of 23
Sector: Medical Products M&A 1 of 1
Type: Add-on Acquisition M&A Deals 3 of 17
State: Maryland M&A 1 of 1
Country: United States M&A 1 of 11
Year: 2007 M&A 2 of 3
Size (of disclosed) 2 of 19
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2007-02-01 Arrow Therapeutics

London, United Kingdom

Arrow Therapeutics utilizes its genome-based target discovery technology to search for novel anti-microbial compounds. The Company is focused on unexplored targets for antibiotics, anti-viral, and anti-fungal therapies and aims to overcome the rapidly growing problem of microbial resistance.

Buy $150M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2007-06-04 DSM Biologics - Manufacturing Facility

Canada

The facility, occupying 66,000 sq. ft, will be used to manufacture antibody drug candidates for clinical trials and will serve the whole of the AstraZeneca group.

Buy -
Mergr

Solution for

Product

Company

Legal